Results 281 to 290 of about 3,949,650 (302)

Newer dopamine quinazolones as anti-parkinsonian agents.

Die Pharmazie, 1985
P, Kumar, C, Nath, K, Shanker
openaire   +1 more source

IV.P2 Dopamine amide conjugates as potent anti-Parkinson's agents

Parkinsonism & Related Disorders, 2006
A. Nayak, D.V. Kohli
openaire   +1 more source

The dopamine receptor: differential binding of d-LSD and related agents to agonist and antagonist states.

Life Science, 1975
Ian Creese, D. R. Burt, Solomon H. Snyder   +2 more
semanticscholar   +1 more source

Novel Agents on the Horizon for Cancer Therapy

Ca-A Cancer Journal for Clinicians, 2009
exaly  

Substituted dopamine quinazolones as potent antiparkinsonian agents.

Die Pharmazie, 1982
P, Kumar, J C, Agarwal, C, Nath, K P, Bhargava, K, Shanker   +4 more
openaire   +1 more source

Binding of β-carbolines and related agents at serotonin (5-HT2 and 5-HT1A), dopamine (D2) and benzodiazepine receptors

, 2000
R. Glennon, M. Dukat, B. Grella, Seoung-Soo Hong, L. Costantino, M. Teitler, Carol Smith, C. Egan, K. Davis, M. Mattson   +9 more
semanticscholar   +1 more source

Have the Serotonin-Dopamine Antagonists Rendered Traditional Antipsychotic Agents Obsolete?

Harvard Review of Psychiatry, 1995
openaire   +2 more sources

DOPAMINE IN CHILDREN: A POTENTIALLY USEFUL INOTROPIC AGENT

InPharma, 1980
openaire   +1 more source

Two inotropic agents: dopamine and dobutamine.

Pediatric nursing, 1988
openaire   +1 more source

[Inotropic agents (Dopamine, Dobutamine, PDE inhibitor)].

Nihon rinsho. Japanese journal of clinical medicine, 2019
openaire   +1 more source